The efficacy, safety and tolerability of Lacrycon® eye drops for the treatment of dry eye syndrome

A review of the efficacy, safety and tolerability of Lacrycon^® eye drops for the treatment of dry eye syndrome.

Article specifications

This review study was published in 2019 in Journal of J Fr Ophtalmol. (IF2017: 2.444) by French specialists. Eight clinical studies (1992-2013) were reviewed. Comparators included phosphate-buffered saline (Phase I) and active controls (Phase II: Lacrisol™; Phase III: Gel-larmes™, Lacrisol, Hyalistil^®, Vismed^®, or the currently prescribed tear substitute). Administration schedules varied from 3 to 8 instillations per day for 7 to 84 days, and evaluation timepoints varied between studies.

 

Results

Lacrycon was better tolerated than most comparators and had a similar safety profile to Vismed. No comparison showed favored the comparator over Lacrycon. These good efficacy, tolerability and safety data support the use of Lacrycon in dry eye syndrome.